of the menstrual cycle (Goodland et al. 1954 ; Takano et al. 1981) . Taking into account above facts just described, we considered that progestational therapy might be relevant to improve sleep apnea syndrome. There being many reports as to progestational therapy applying to Pickwickian syndrome or OSA, the evaluations for its usefulness are not consistent, i.e., some investigators asserted that it is effective (Lyons and Huang 1968; Sutton et al. 1975 ; Hensley et al. 1980 ), and others not (Orr et al. 1979) . The progestational agents which they applied were progesterone by intramuscular injection (Lyons and Huang 1968) , or medroxyprogesterone acetate (Sutton et al. 1975; Orr et al. 1979; Hensley et al. 1980) . In this report, we used chlormadinone acetate (CMA) of which we have already reported as a potent respiratory stimulant (Kimura et al. 1984 ).
CASE REPORT Case 1. A 48-year-old male was admitted because of obesity and daytime somnolence. He had gained weight gradually since 25-year-old, exceeding 100 kg at 42-year-old, and complained of dyspnea on exersion, palpitation and daytime somnolence. There was history suffering from hypertension for 10 years. His height and body weight were 166 cm and 110.0 kg, and obesity index was + 85% by Broca's method. On admission, his blood pressure was 158/100 mm g. Tachypnea (32 times/min), slightly cyanotic lips and pretibial pitting edema were recognized. Mild polycythemia (RBC 572 x 10", Ht 50.3%) and mild hypercapnia with normoxia (PaCO2 47.8 mmHg, Pa02 88.3 mmHg, pH 7.36) were observed. Flow volume curve showed slightly obstructive pattern in the upper airway, however, pulmonary functions were within normal range. Electro-cardiogram (ECG) represented the tendency to right ventricular hypertrophy (deep S in V5, V6). After treatment for edema, he was examined as to resting arterial blood gas, HVR and HCVR with and without inspiratory flow-resistive loading (16 cmH2O/liter/sec). At the same time, sleep study was performed. Electroencephalography (EEG), electrooculography (EOG), electromyography (EMG) of the mentalis muscle, and ECG were recorded. Respiratory effort was assessed by inductance plethysmography (Respitrace) to monitor movement of the rib-cage and the abdomen. Simultaneously, nose or mouth airflow by a flow-thermister was assessed to ascertain the occurrence of apnea. Sleep apnea was analyzed by conventional criteria, i.e., cessation of airflow over 10 sec was considered as apnea. He was administered CMA at a dose of 50 mg/day for 7 days, and above tests were performed before and the 7th day during CMA treatment. His body weight was not changed during CMA administra tion. PaCo2 decreased from 42.0 to 35.5 mmHg without any change in Pa02 as shown were obesity and daytime somnolence. His height and body weight were 157 cm and 92.2 kg, and obesity was amounted to +93% by Broca's method. Mild polycythemia (RBC 577 x 104, lit 51.1%) and hypercapnia with hypoxia (PaC02 46.6, Pa02 79.2, pH 7.36) were noted. Pulmonary functions revealed normal values, although definitive right ventricular hypertrophy (right axis deviation, deep Sin V5, R/S in V5=0.8) was noted. During CMA treatment for 7 days his body weight was constantly presserved. Arterial blood gas was changed as Table 1 , indicating improvement both hypercapnia and hypoxia by CMA, HVR, HCVR and impaired load compensation were augmented as shown in Table 2 . Both central and obstructive apnea were observed before CMA administration, however, the former disappeared by CMA, although OSA was remained with improvement in severity. Table 3 summarizes the sleep study, demonstrating apparent improvement of oxygen desaturation by CMA.
DISCUSSION
Improved nocturnal oxygen desaturation was accompanied with increased ventilatory response to CO, and hypoxia at daytime. Simultaneously, augmenta tion in load compensation also ensued.
In case 1, CMA administration induced qualitative change in obstructive sleep apnea, so that obstructive hypopnea became manifest. This may have been derived by increased respiratory drive in the upper airway muscle. Such mecha nism may be justified by the report presented by St. John et al. (1986) that respiratory motor discharge to the upper airway muscle was increased by medroxy progesterone acetate (MPA) via activation of the reticular activating system. On the other hand, the development of load compensation was known to be mediated by the higher central nervous system function (Isaza et al. 1976 ), as load compen sation disappeared during sleep (Santiago et al. 1981) . So augmented load compensation might be useful to preserve an appropriate ventilation at night if arousal response is related to the re-opening of the upper airway (Phillipson and Sullivan 1978) . Moreover, it is reported that, even during wakefulness, the patients with OSA could not exhibit load compensation (Rajagopal et al. 1984) and they showed the elevated threshold to detect inspiratory loading (McNicholas et al. 1984) . From these considerations, augmented load compensation was inferred to be related with improvement in OSA. In case 2, the improvement in OSA was accompaied with disappearance of central apnea. Onal et al. (1981) claimed that the cause of OSA may involve abnormality in the central mechanism of control of breathing, indicating impairment in both upper airway and respira tory muscle function, rather than the upper airway dysfunction alone. The finding observed in case 2 might support the idea that CMA affects through central nervous system mechanism.
More cases should be precisely studied to evaluate the effectiveness of proges terone in patients with sleep apnea syndrome.
